New hope for PBC patients: phase 3 trial of saroglitazar launches
NCT ID NCT07424677
First seen Feb 26, 2026 · Last updated Jun 09, 2026 · Updated 13 times
Summary
This study tests a new drug, saroglitazar magnesium, in 89 adults with primary biliary cholangitis (PBC) who did not get enough benefit from or could not tolerate standard treatment (UDCA). The goal is to see if the drug can lower a key liver enzyme (alkaline phosphatase) to normal levels. Participants will receive either the drug or a placebo, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.